Document › Details

PharmaMar S.A.. (1/18/18). "Press Release: Pharma Mar, S.A. Announces the Results of the Phase III Clinical Trial (CORAIL) with Zepsyre (lurbinectedin) in Platinum-resistant Ovarian Cancer patients". Colmenar Viejo (Madrid).

	Organisation	PharmaMar S.A. (MSE: PHM)
	Group	PharmaMar (Group)
	Product	Zepsyre®
	Product 2	clinical research

Pursuant to article 228 of the consolidated text of the Spanish Securities Market Act, we hereby inform you of the following SIGNIFICANT EVENT:

“Pharma Mar, S.A. announces the results of the Phase III clinical trial (CORAIL) with Zepsyre® (lurbinectedin) in platinum-resistant ovarian cancer patients.

The CORAIL trial, comparing Zepsyre® versus topotecan or PLD (liposomal doxorubicin) in platinum resistant ovarian cancer patients has not met the primary end-point of the trial, which was PFS (Progression Free Survival).

The antitumoral activity of the three compounds Zepsyre®, topotecan and PLD, in terms of PFS, has been the same. In the CORAIL trial Zepsyre® has demonstrated a better safety profile than the control arm.

Results of this trial will be presented at future oncology congresses.”

Pharma Mar S.A. Avda. de los Reyes, 1 P.I. La Mina 28770 Colmenar Viejo (Madrid) Spain Ph.: +34 91 846 6000 Fax.: +34 91 846 6001 www.pharmamar.com

Record changed: 2018-01-25

More documents for PharmaMar (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]